Compass Therapeutics (CMPX) Free Cash Flow (2018 - 2026)
Compass Therapeutics (CMPX) reported Free Cash Flow of -$17.4 million for Q1 2026, down 31.19% on a YoY basis from -$25.2 million in Q1 2025, and down 30.91% sequentially from -$13.3 million in Q4 2025.
Compass Therapeutics (CMPX) Free Cash Flow (2018 - 2026) Analysis & Trends
Compass Therapeutics (CMPX) has 9 years of Free Cash Flow data on file, last reported at -$17.4 million in Q1 2026.
- For the quarter ending Q1 2026, Free Cash Flow fell 31.19% year-over-year to -$17.4 million; the trailing twelve-month figure through Mar 2026 stood at -$53.3 million (down 20.47% YoY), and the FY2025 full-year result was -$49.2 million, down 9.51% from the prior year.
- Free Cash Flow fell to -$17.4 million in Q1 2026, from -$13.3 million in the prior quarter.
- In the past five years, Free Cash Flow ranged from a high of -$4.5 million in Q2 2022 to a low of -$17.4 million in Q1 2026.
- A 5-year average of -$11.0 million and a median of -$11.0 million in 2022 frame the typical range for Free Cash Flow.
- Across the five-year window, Free Cash Flow plunged 163.36% in 2022 and surged 46.19% in 2023, its largest moves.
- Tracing CMPX's Free Cash Flow over 5 years: stood at -$10.7 million in 2022, then fell by 15.6% to -$12.4 million in 2023, then increased by 25.89% to -$9.2 million in 2024, then tumbled by 44.66% to -$13.3 million in 2025, then tumbled by 30.91% to -$17.4 million in 2026.
- Business Quant data shows CMPX's Free Cash Flow at -$17.4 million in Q1 2026, -$13.3 million in Q4 2025, and -$10.9 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Free Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - | -19.58 Mn |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | -2.49 Mn |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn | 158.09 Mn |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn | 1.29 Bn |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn | 848.30 Mn |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - | - |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn | - |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - | -354.95 Mn |
| 10 | Compass Therapeutics | 388.64 Mn | 193.96 Mn | - | -17.35 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -17.35 Mn |
| Mar 31, 2026 | -17.35 Mn |
| Dec 31, 2025 | -13.25 Mn |
| Dec 31, 2025 | -13.25 Mn |
| Sep 30, 2025 | -10.86 Mn |
| Sep 30, 2025 | -10.86 Mn |
| Jun 30, 2025 | -11.83 Mn |
| Jun 30, 2025 | -11.83 Mn |
| Mar 31, 2025 | -13.23 Mn |
| Mar 31, 2025 | -13.23 Mn |
| Dec 31, 2024 | -9.16 Mn |
| Dec 31, 2024 | -9.16 Mn |
| Sep 30, 2024 | -11.10 Mn |
| Sep 30, 2024 | -11.10 Mn |
| Jun 30, 2024 | -10.75 Mn |
| Jun 30, 2024 | -10.75 Mn |
| Mar 31, 2024 | -13.89 Mn |
| Mar 31, 2024 | -13.89 Mn |
| Dec 31, 2023 | -12.36 Mn |
| Dec 31, 2023 | -12.36 Mn |